Merck Branding - Search News

Merck, Keytruda and WSJ

New version of Merck's Keytruda faces possible patent battle, WSJ reports

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

The Wall Street Journal on MSN · 3d

New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Seeking Alpha on MSN · 4d

Merck set for patent battle with Halozyme over injectable Keytruda: WSJ

A new patent dispute is brewing between Halozyme Therapeutics (NASDAQ:HALO), a biotech focused on drug delivery technology, and Merck (NYSE:MRK) over an injectable version of the New Jersey-based pharma giant’s cancer blockbuster,

Pharmaceutical Technology on MSN2d

Merck KGaA reports YE24 earnings growth amid SpringWorks acquisition talks

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

24/7 Wall St29d

Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What's Next?

Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name drugs such as Keytruda, and the myriad of commercials the company shows ...

Morningstar1mon

Merck Earnings: Gardasil Weighs on 2025 Growth, but Firm Still Undervalued

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Merck, Keytruda and WSJ

Trending now